The National Advisory Committee on Immunization (NACI) recommends that SHINGRIX should be offered to adults 50 years of age and older (strong recommendation). 2
According to NACI, a strong recommendation applies to most individuals and should be followed unless a clear and compelling rationale for an alternative approach is present. 2
Refer to the NACI statement on the Public Health Agency website for further information.
The Comité sur l'immunisation du Québec (CIQ) preferentially recommends SHINGRIX for adults 50 years of age and older. 3‡
SHINGRIX is indicated for the prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older. 1
The Scientific Rationale Video provides an engaging and easily understood look into the science behind the development of SHINGRIX.
Patients with a known hypersensitivity to the active substance or to any component of the vaccine.
Administration: Do not administer the vaccine intravascularly, intradermally or subcutaneously.
Please consult the product monograph at gsk.ca/SHINGRIX/PM for important information relating to dosing and administration, adverse reactions, contraindications and drug interactions which have not been discussed in this piece. To request a product monograph, or to report an adverse event please call 1-800-387-7374.
* Clinical significance has not been established.
† Modified Total Vaccinated Cohort (mTVC) was the primary efficacy analysis and included all subjects randomized in the study who received a second dose of the vaccine and did not develop a confirmed case of shingles within one month after the second dose.
‡ Reproduction of information from the PIQ, 7th ed. Zona-SU section; http://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/zona-su-vaccin-sous-unitaire-contre-le-zona/
The original French version of this information was published in 2018 by the Department of Health and Social Services. The Dept. declines any responsibility for any damage, loss or injury that may result from this translation into English. In case of contradiction between the English and French versions of this information, the latter it will prevail. The Government of Quebec is and remains the only copyright owner of the work in French. The English version has not been validated by the Ministry of Health and Social Services.